{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(12)"],"submitter":["Kadowaki T"],"funding":["Nippon Boehringer Ingelheim Co., Ltd","Eli Lilly"],"pubmed_abstract":["<h4>Aim</h4>To evaluate the persistence with oral antidiabetic drug (OAD) treatment characterized by drug class, patient characteristics and severity of renal impairment (RI) in patients with type 2 diabetes (T2DM) in Japan.<h4>Materials and methods</h4>This retrospective, observational study extracted data from a large-scale hospital database (April 2008 to September 2016). Patients with T2DM aged ≥40 years on the day of their first prescription (index date) of any OAD (biguanides [BGs], thiazolidinediones [TZDs], sulphonylureas [SUs], glinides, dipeptidyl peptidase-4 [DPP-4] inhibitors, or α-glucosidase inhibitors [α-GIs]) available between January 1, 2014 and September 30, 2016 were identified. Sodium-glucose co-transporter-2 inhibitors were not available at study initiation. Treatment "],"journal":["Diabetes, obesity & metabolism"],"pagination":["2830-2839"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6282986"],"repository":["biostudies-literature"],"pubmed_title":["Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics and severity of renal impairment: A Japanese database analysis."],"pmcid":["PMC6282986"],"pubmed_authors":["Urushihara H","Hirakawa T","Sarai N","Taki K","Kadowaki T","Iwasaki K"],"additional_accession":[]},"is_claimable":false,"name":"Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics and severity of renal impairment: A Japanese database analysis.","description":"<h4>Aim</h4>To evaluate the persistence with oral antidiabetic drug (OAD) treatment characterized by drug class, patient characteristics and severity of renal impairment (RI) in patients with type 2 diabetes (T2DM) in Japan.<h4>Materials and methods</h4>This retrospective, observational study extracted data from a large-scale hospital database (April 2008 to September 2016). Patients with T2DM aged ≥40 years on the day of their first prescription (index date) of any OAD (biguanides [BGs], thiazolidinediones [TZDs], sulphonylureas [SUs], glinides, dipeptidyl peptidase-4 [DPP-4] inhibitors, or α-glucosidase inhibitors [α-GIs]) available between January 1, 2014 and September 30, 2016 were identified. Sodium-glucose co-transporter-2 inhibitors were not available at study initiation. Treatment ","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Dec","modification":"2026-05-06T01:40:12.496Z","creation":"2019-03-27T00:12:18Z"},"accession":"S-EPMC6282986","cross_references":{"pubmed":["29974673"],"doi":["10.1111/dom.13463"]}}